7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan Irinotecan, a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer. SN 38 has been used in trials studying the treatment of Cancer, Advanced Solid Tumors, Small Cell Lung Cancer, Metastatic Colorectal Cancer, and Triple Negat...
Investigated for use/treatment in colorectal cancer.
M D Anderson Cancer Center, Houston, Texas, United States
Houston Methodist Hospital ( Site 0419), Houston, Texas, United States
Cardiomed SRL Cluj-Napoca ( Site 0217), Cluj-Napoca, Cluj, Romania
Infirmary Cancer Care ( Site 0418), Mobile, Alabama, United States
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Gustave Roussy, Villejuif, France
Hospital Universitario Donostia, San Sebastián, Donostia, Spain
Hospital Universitario General de Catalunya, Sant Cugat Del Vallès, Barcelona, Spain
Hospital Arnau de Vilanova, Lleida, Spain
Florida Cancer Specialists - North Region Research Office,521 North Lecanto Highway, Lecanto, Florida, United States
Florida Cancer Specialists,1100 Goodlette Road, Naples, Florida, United States
Florida Cancer Specialists,681 4th Avenue North, Naples, Florida, United States
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
Magee-Womens Hospital of UPMC,5115 Centre Avenue, Pittsburgh, Pennsylvania, United States
Universitätsklinikum Ulm, Ulm, Bayern, Germany
Universitätsklinikum Carl-Gustav-Carus, Dresden, Sachsen, Germany
National Center for Tumor Diseases, Heidelberg, Baden-Wuerttemberg, Germany
Beacon Cancer Care, Coeur d'Alene, Idaho, United States
University of Kansas Medical Center Research Institute, Inc. - 3901 Rainbow (MAIN), Kansas City, Kansas, United States
Johns Hopkins University, Baltimore, Maryland, United States
IRCCS Ospedale San Raffaele, Milan, Italy
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.